Elanco Animal Health (ELAN) said Tuesday it was partnering with MedGene to help commercialize the company's vaccine to help prevent avian influenza in dairy cattle.
Medgene previously met all of the US Department of Agriculture's requirements for its bovine vaccine platform technology, which is now in the final stages of review ahead of an expected conditional license approval, the companies said.
The prior USDA authorization also allowed Medgene to accelerate development of its H5N1 vaccine as well as adapting its existing vaccine manufacturing to protect the US dairy herd, the companies said.
Elanco shares were falling over 7% in early Tuesday trading after the company reported Q4 earnings that missed Wall Street expectations and also guided 2025 results below analyst consensus calls.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。